Technical Analysis for ESLA - Estrella Immunopharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Fell Below 50 DMA | Bearish | -1.92% | |
180 Bearish Setup | Bearish Swing Setup | -1.92% | |
NR7 | Range Contraction | -1.92% | |
NR7-2 | Range Contraction | -1.92% | |
Narrow Range Bar | Range Contraction | -1.92% | |
Gapped Down | Weakness | -1.92% | |
Crossed Above 50 DMA | Bullish | -8.93% |
Alert | Time |
---|---|
Outside Day | about 11 hours ago |
Bearish 180 Entry | about 11 hours ago |
Fell Below Previous Day's Low | about 11 hours ago |
Down 1% | about 11 hours ago |
Possible NR7 | about 12 hours ago |
Get a Trading Assistant
- Earnings date: Unknown
Estrella Immunopharma, Inc. Description
Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer. To accomplish this mission, Estrella's lead product candidate, EB103, utilizes Eureka's ARTEMIS® technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which also utilizes Eureka's ARTEMIS® technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. Estrella is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus ("CF33-CD19t"), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors using a "mark and kill" strategy.
Classification
Sector: Financial Services
Industry: Shell Companies
Keywords: Cancer Solid Tumors Immune System Blood Cancers CD19 Oncolytic Virus Preclinical Stage Biopharmaceutical Cd22
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 33.0 |
52 Week Low | 0.8634 |
Average Volume | 33,187 |
200-Day Moving Average | 3.73 |
50-Day Moving Average | 1.09 |
20-Day Moving Average | 1.11 |
10-Day Moving Average | 1.06 |
Average True Range | 0.10 |
RSI (14) | 44.13 |
ADX | 24.03 |
+DI | 18.31 |
-DI | 15.10 |
Chandelier Exit (Long, 3 ATRs) | 1.00 |
Chandelier Exit (Short, 3 ATRs) | 1.30 |
Upper Bollinger Bands | 1.25 |
Lower Bollinger Band | 0.98 |
Percent B (%b) | 0.17 |
BandWidth | 24.39 |
MACD Line | -0.02 |
MACD Signal Line | -0.01 |
MACD Histogram | -0.0091 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.10 | ||||
Resistance 3 (R3) | 1.10 | 1.09 | 1.08 | ||
Resistance 2 (R2) | 1.09 | 1.07 | 1.08 | 1.08 | |
Resistance 1 (R1) | 1.05 | 1.06 | 1.05 | 1.05 | 1.07 |
Pivot Point | 1.04 | 1.04 | 1.03 | 1.03 | 1.04 |
Support 1 (S1) | 1.00 | 1.02 | 1.00 | 1.00 | 0.97 |
Support 2 (S2) | 0.99 | 1.01 | 0.98 | 0.96 | |
Support 3 (S3) | 0.95 | 0.99 | 0.96 | ||
Support 4 (S4) | 0.95 |